| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets (NCT07511010) | Chipscreen Biosciences, Ltd. | 2026-10-08 |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes (NCT07580638) | Chipscreen Biosciences, Ltd. | 2026-07-18 |
| Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets (NCT07519265) | Chipscreen Biosciences, Ltd. | 2026-07-09 |
| A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma (NCT07583771) | Chipscreen Biosciences, Ltd. | 2026-06-01 |
| Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (NCT07445295) | Chipscreen Biosciences, Ltd. | 2026-03-31 |
| A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis (NCT07129382) | Chipscreen Biosciences, Ltd. | 2025-09-08 |
| Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (NCT06947967) | Chipscreen Biosciences, Ltd. | 2025-08-12 |
| Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors (NCT06902350) | Chipscreen Biosciences, Ltd. | 2025-05-21 |
| A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients (NCT06497985) | Chipscreen Biosciences, Ltd. | 2024-12-06 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules (NCT06224595) | Chipscreen Biosciences, Ltd. | 2024-03-28 |
| A Study of CS23546 in Subjects With Advanced Tumors (NCT06245122) | Chipscreen Biosciences, Ltd. | 2024-03-27 |
| A Study of NWY001 in Subjects With Advanced Solid Tumors (NCT05979155) | Chipscreen Biosciences, Ltd. | 2024-01-05 |
| A Clinical Trial of CS12192 in Healthy Subjects (NCT05922709) | Chipscreen Biosciences, Ltd. | 2023-07-20 |
| Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. (NCT05681273) | Chipscreen Biosciences, Ltd. | 2023-02-17 |
| Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function (NCT05515445) | Chipscreen Biosciences, Ltd. | 2022-12-03 |
| Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function (NCT05515458) | Chipscreen Biosciences, Ltd. | 2022-11-20 |
| A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC (NCT05519865) | Chipscreen Biosciences, Ltd. | 2022-10-26 |
| Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. (NCT05271292) | Chipscreen Biosciences, Ltd. | 2022-08-26 |
| Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) (NCT05497843) | Chipscreen Biosciences, Ltd. | 2022-08-25 |
| Mass Balance Study of [14C]Chiauranib (NCT05371899) | Chipscreen Biosciences, Ltd. | 2022-07-20 |
| Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers (NCT05346601) | Chipscreen Biosciences, Ltd. | 2022-06-02 |
| A Phase II Clinical Trial of Chiglitazar for NASH (NCT05193916) | Chipscreen Biosciences, Ltd. | 2022-03-21 |
| Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (NCT04921527) | Chipscreen Biosciences, Ltd. | 2021-12-20 |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. (NCT05068427) | Chipscreen Biosciences, Ltd. | 2021-11-23 |
| A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (NCT05336721) | Chipscreen Biosciences, Ltd. | 2021-11-05 |
| Chiglitazar Added to Metformin for Type 2 Diabetes (NCT04807348) | Chipscreen Biosciences, Ltd. | 2021-07-06 |
| Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (NCT04231448) | Chipscreen Biosciences, Ltd. | 2020-05-21 |
| Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NCT03974243) | Chipscreen Biosciences, Ltd. | 2019-07-11 |
| Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer (NCT03901118) | Chipscreen Biosciences, Ltd. | 2019-07-01 |
| Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma (NCT03245190) | Chipscreen Biosciences, Ltd. | 2018-04-28 |
| Phase Ib Study of Chiauranib in Patients With Ovarian Cancer (NCT03166891) | Chipscreen Biosciences, Ltd. | 2017-12-15 |
| Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer (NCT03216343) | Chipscreen Biosciences, Ltd. | 2017-11-09 |